Glycoera Ag Raises Chf 45 Million (Us$ 49 Million) Series A Financing To Develop Novel Biologics Based On Innovative Glycoengineering Platform
Nov 05, 2021•over 3 years ago
Round Type
series a
Description
GlycoEra AG announced today the close of a CHF 45 million ($49 million) Series A financing round, co-led by renowned US and European life science investors, 5AM Ventures, Roche Venture Fund and Sofinnova Partners. LimmaTech Biologics AG, from which GlycoEra was spun-out, also participated in this round. The proceeds will be used to support the growth of the company and to demonstrate the breadth and value of its CustomGlycan Platform technology in developing assets that can unlock unique biological activities for therapeutic targets in several disease indications.
FundzWatch™ Score
75
Medium Activity
Buyer Intent Analysis
Get personalized insights on buying likelihood